Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1964 2
1965 3
1966 1
1967 7
1968 2
1969 13
1970 11
1971 6
1972 10
1973 2
1974 6
1975 8
1976 4
1977 5
1978 7
1979 5
1980 5
1981 5
1982 10
1983 13
1984 13
1985 12
1986 15
1987 19
1988 8
1989 25
1990 23
1991 18
1992 26
1993 38
1994 19
1995 26
1996 28
1997 38
1998 36
1999 39
2000 32
2001 46
2002 50
2003 37
2004 40
2005 61
2006 57
2007 84
2008 64
2009 85
2010 99
2011 112
2012 97
2013 112
2014 108
2015 140
2016 128
2017 131
2018 127
2019 128
2020 123
2021 168
2022 137
2023 124
2024 127
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,631 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP; KEYNOTE-181 Investigators. Kojima T, et al. Among authors: doi t. J Clin Oncol. 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7. J Clin Oncol. 2020. PMID: 33026938 Clinical Trial.
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. Tsurutani J, et al. Among authors: doi t. Cancer Discov. 2020 May;10(5):688-701. doi: 10.1158/2159-8290.CD-19-1014. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213540 Free PMC article. Clinical Trial.
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Modi S, et al. Among authors: doi t. J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058843 Free PMC article. Clinical Trial.
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Cutsem EV, Winkler RE, Makris L, Ilson DH, Tabernero J. Shitara K, et al. Among authors: doi t. Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Lancet Oncol. 2018. PMID: 30355453 Clinical Trial.
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.
Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S. Janku F, et al. Among authors: doi t. Cancer Immunol Res. 2022 Dec 2;10(12):1441-1461. doi: 10.1158/2326-6066.CIR-21-0722. Cancer Immunol Res. 2022. PMID: 36129967 Clinical Trial.
[No title available]
Jin K, Kawasaki K, Doi T, Uene M, Kanbara M. Jin K, et al. Among authors: doi t. Nihon Koshu Eisei Zasshi. 2015;62(12):739. doi: 10.11236/jph.62.12_739. Nihon Koshu Eisei Zasshi. 2015. PMID: 26781625 Free article. Japanese. No abstract available.
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.
Tsuge A, Watanabe S, Kawazoe A, Togashi Y, Itahashi K, Masuda M, Sai A, Takei S, Muraoka H, Ohkubo S, Sugiyama D, Yan Y, Fukuoka S, Doi T, Shitara K, Koyama S, Nishikawa H. Tsuge A, et al. Among authors: doi t. Cancer Immunol Res. 2024 Nov 27. doi: 10.1158/2326-6066.CIR-24-0713. Online ahead of print. Cancer Immunol Res. 2024. PMID: 39602577
Endothelial ROBO4 suppresses PTGS2/COX-2 expression and inflammatory diseases.
Tanaka M, Shirakura K, Takayama Y, Μatsui M, Watanabe Y, Yamamoto T, Takahashi J, Tanaka S, Hino N, Doi T, Obana M, Fujio Y, Takayama K, Okada Y. Tanaka M, et al. Among authors: doi t. Commun Biol. 2024 May 18;7(1):599. doi: 10.1038/s42003-024-06317-z. Commun Biol. 2024. PMID: 38762541 Free PMC article.
2,631 results